Targeting therapy for breastcancer

Targeting therapy for breastcancer

Leiden, July 2025 – GenLumina has reached a preclinical milestone with our controlled Antibody Drug Conjugate (ADC) showing efficacy against breast cancer cells. We have successfully conjugated our drug payload to an established therapeutic antibody used in breast...
Annual Report 2025

Annual Report 2025

Reflecting on a Year of Progress The Foundation Building a biotech company is a journey that requires patience, perseverance, and a strong foundation. As we look back on the past year, we are proud of the progress we have made and the milestones we have achieved...
The last mile in precision oncology (CRIG)

The last mile in precision oncology (CRIG)

Gent – Belgium, 6 February 2026 GenLumina presented the last mile in precision oncology; our approach to precision cancer treatment. It was exciting to exchange perspectives with others working on targeting therapies that recognize overexpressed markers on...
Kansen voor West

Kansen voor West

Leiden, 19-01-2026   We are pleased to announce that GenLumina has been awarded an Advice Innovation Voucher by Kansen voor West. This voucher enables GenLumina to access expert support through the Unlock_incubator, helping to shape our business strategy and...
IP granted by Netherlands Patent Office

IP granted by Netherlands Patent Office

GenLumina is pleased to announce that the Netherlands Patent Office has officially granted our patent based on the application filed on 24 April 2023. This milestone reinforces the scientific foundation of GenLumina’s light-activated nanomedicine platform and...
New Step in Targeted Cancer Therapy

New Step in Targeted Cancer Therapy

Leiden, September 3 – We are thrilled to announce that GenLumina has secured funding from Health~Holland to support a collaborative project with LUMC. This grant will enable us to accelerate the development of our light-activated cancer therapy by expanding our...